ADAPY — Adaptimmune Therapeutics PLC
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1621227 ·
United Kingdom
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 13,677,000 | 11,176,000 | -29,717,000 | -30,340,000 | 130,633,000 | 26,061,000 | 201,591,000 |
| Mar 2025 | 7,285,000 | 6,406,000 | -44,071,000 | -47,584,000 | 158,072,000 | 41,054,000 | 195,501,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-135,576,000
Investing CF
$67,811,000
Financing CF
$-23,665,000
CapEx
$-2,451,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,171,911,000
Inventory
$11,411,000
Receivables
$28,895,000
ST Investments
$0
EBIT TTM
$-144,703,000
Pretax Income TTM
$-149,259,000
Interest Exp TTM
$4,556,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,924,000
EBITDA
$-57,491,000
Free Cash Flow
$-61,613,752
Enterprise Value
$-4,182,503
Total Cash
$25,951,000
Total Debt
$14,082,000
Shares Out
265,051,591
Trailing EPS
$-0.67
Book Value
$0.12
ROE
-346.7%
ROA
-25.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 178,032,000 | -52,409,000 | -70,814,000 | 245,963,000 | 234,114,000 | 11,849,000 | -73,206,000 |
| Dec 2023 | 60,281,000 | -138,038,000 | -113,871,000 | 282,616,000 | 243,103,000 | 39,513,000 | -140,880,000 |
| Dec 2022 | 27,148,000 | -163,965,000 | -165,456,000 | 328,916,000 | 247,038,000 | 81,878,000 | -141,769,000 |
| Dec 2021 | 6,149,000 | -162,246,000 | -158,090,000 | 469,545,000 | 263,585,000 | 205,960,000 | 10,729,000 |
TTM Snapshot
Revenues TTM
$65,085,000
NetIncome TTM
$-169,756,000
OpCashFlow TTM
—
Assets (Latest)
$130,633,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $247.70B | $457.93 | — |
| GILD | GILEAD SCIENCES, INC. | $211.18B | $170.26 | — |
| MRNA | Moderna, Inc. | $82.56B | $206.80 | — |
| ARGX | ARGENX SE | $58.92B | $947.52 | — |
| BIIB | BIOGEN INC. | $37.07B | $250.79 | — |
News headlines (Yahoo Finance, 1h cache)
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
2026-07-27 15:54 · Yahoo
Flagship Pioneering Appoints Adrian Rawcliffe as CEO-Partner and CEO of Etiome
2026-01-08 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.